

Butanol extract of *Ecklonia cava* prevents production and aggregation of beta-amyloid, and reduces beta-amyloid mediated neuronal death.

Kang IJ, Jeon YE, Yin XF, Nam JS, You SG, Hong MS, Jang BG, Kim MJ.

Abstract

Beta-amyloid (A β) is a major pathogenic peptide for Alzheimer's disease (AD) and is generated by the processing of amyloid precursor protein (APP). The A β monomers aggregate into oligomeric and fibrillar forms which have been implicated as the toxic species inducing the neuronal dysfunction. Brown algae *Ecklonia cava* is known for its anti-oxidant and anti-inflammatory functions. Therefore, we tested the effect of *E. cava* extract on the production and aggregation of A β peptides. The butanol extract of *E. cava* reduced A β secretion from HEK293 cells expressing APP with Swedish mutation and increased soluble APP α and C-terminal fragment- α (CTF α), of which activity was similar to BACE (β -site of APP cleaving enzyme) inhibitors. Furthermore, the extract inhibited A β oligomerization, particularly mid-size oligomer formation, confirmed by the ultrastructural morphology. Congo red, thioflavin T assays, and electron microscopy showed that the extract inhibited A β fibril formation effectively. Finally, the extract protected primary cortical neurons from various A β -induced cell deaths, especially oligomer-induced death. Although further study is needed to test the effectiveness of the extract in vivo, our results demonstrate, for the first time, that the butanol extract of *E. cava* could be used as an anti-A β agent for AD therapeutics.